Decision Aids for Prostate Cancer Screening Choice

This systematic review and meta-analysis of 19 randomized clinical trials estimates the association of decision aids with decisional outcomes in prostate cancer screening.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research

Related Links:

Sepsis is a healthcare condition with “incredible unmet need,” Ajay Shah, cofounder and CEO of Cytovale, tells MD+DI. “More people die from sepsis than from breast cancer, prostate cancer, and AIDS combined each year, and it costs more than $20 billion a year to treat sepsis in the United States.” Complicating matters is that sepsis “is challenging to diagnose early in the emergency department,” he added. Cytovale is hoping to tackle sepsis through early diagnosis. The company is developing a diagnostic test that cou...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
Publication date: Available online 31 October 2019Source: International Journal of PharmaceuticsAuthor(s): Mohammadjavad Jahanshahi, Elaheh Kowsari, Vahid Haddadi-Asl, Mehdi Khoobi, Jong Hyun Lee, Firoz Babu Kadumudi, Sepehr Talebian, Nazila Kamaly, Mehdi MehraliAbstractFluorinated graphene has recently gained much attention for cancer drug delivery, owing to its peculiar properties including high electronegativity difference, magnetic resonance imaging contrast agent, and the photothermal effect. However, the hydrophobic nature of fluorinated graphene greatly hinders its application as a biological material. Herein, a nov...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
When it comes to prostate cancer screening, decision aids cannot replace a conversation between a man and his physician.Medscape Urology
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Urology Commentary Source Type: news
How clinically effective is MRI-guided biopsy for prostate cancer? The modality...Read more on AuntMinnie.comRelated Reading: Which biopsy method best detects prostate cancer? AIUM: TRUS or MRI for prostate diagnosis? MRI-guided cryoablation a boon for HCC patients Multiparametric MRI aids in prostate cancer follow-up Societies eye role for prostate MRI-guided biopsy
Source: Headlines - Category: Radiology Source Type: news
Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach makin...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Technical advance Source Type: research
This study describes the development and i...
Source: BMC Medical Research Methodology - Category: Research Authors: Tags: Research article Source Type: research
To evaluate barriers to implementation of patient decision aids (PDAs) issued in an electronic medical record (EMR). We undertook an implementation outcomes analysis focused on what proportion of men eligible for the PDA received it (penetration), and of the men who received it, how many used it as intended (fidelity). We also evaluated various patient centered outcomes related to decision making.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
AbstractUptake of decision aids (DAs) in daily routine is low, resulting in limited knowledge about successful DA implementation at a large scale. We assessed implementation rates after multi-regional implementation of three different prostate cancer (PCa) treatment DAs and patient-perceived barriers and facilitators to use a DA. Thirty-three hospitals implemented one out of the three DAs in routine care. Implementation rates for each DA were calculated per hospital. After deciding about PCa treatment, patients (n = 1033) completed a survey on pre-formulated barriers and facilitators to use a DA. Overall DA i...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
Interview with Kari A O Tikkinen, MD, PhD, author of Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Source Type: podcasts
In 2009, routine prostate cancer screening using a prostate-specific antigen (PSA) test was described as “the controversy that refuses to die.”(p1351) Unfortunately, 10 years later, the controversy is still alive and thriving. Clinical trials have failed to resolve whether or to what degree screening using PSA tests help reduce prostate cancer –specific mortality, and it has long been clear that PSA screening tests increase the diagnosis of low-risk cancers and can lead to patient harm from potentially unnecessary biopsies and cancer treatment. As a result, many expert groups recommend shared decision-mak...
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | HIV AIDS | Internal Medicine | Prostate Cancer